在人工智能驱动下识别了一种选择性双重功能抑制剂,阻断HK2活性和HK2-VDAC1相互作用,在低氧条件下显示增强的抗癌疗效
Wenying Shan1, Shao-Lin Zhang2, Yehuda G Assaraf3
1Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China; MoE Frontiers Science Centre for Precision Oncology, University of Macau, Taipa, Macau SAR, China.
一个新型的人工智能工具识别了化合物106,一种选择性六酶2抑制剂 (HK2i). 这种化合物通过阻断糖解和诱导癌细胞的亡,显示出作为抗癌疗法的前景.
科学领域:
- 生物化学和分子生物学
- 癌症研究和治疗学
- 计算化学和药物发现
背景情况:
- 赫索金酶2 (HK2) 在华堡效应中起着至关重要的作用,通过与电压依赖阳离子通道1 (VDAC1) 的相互作用促进糖解,并赋予抗亡性质.
- 向HK2是癌症治疗的一个有希望的策略,因为它启动了糖解和乳酸生产,但目前还没有临床HK2抑制剂 (HK2is).
研究的目的:
- 使用基于AI的化合物-蛋白质相互作用 (CPI) 预测工具 (GCVec) 与分子对接相结合,识别新型HK2抑制剂 (HK2is).
- 为了评估所识别的化合物106作为潜在的抗癌治疗剂的疗效.
主要方法:
- 利用GCVec AI工具和分子对接来预测和识别潜在的HK2抑制剂.
- 评估了化合物106对HK2酶 (IC50,Kd) 的抑制活性及其对HK2-VDAC1相互作用的影响.
- 评估了化合物106在SW480结直肠癌细胞中的抗癌功效,包括其对糖解,乳酸生产,ATP水平和亡标志物的影响.
主要成果:
- 化合物106证明了HK2酶的强烈抑制,其IC50为0.79 ± 0.07μM,Kd为0.41 ± 0.03μM.
- 化合物106有效地阻断了HK2-VDAC1相互作用,并且在高HK2/VDAC1水平的癌细胞中在缺氧下显示出增强的抗癌疗效.
- 选择性抑制SW480结肠直肠癌细胞 (IC50 = 5.00 ± 0.94μM),减少乳酸和ATP,以及诱导的亡标志物 (增加p-AMPK/AMPK,Bax;减少Bcl2).
结论:
- GCVec成功识别了106化合物,一种新型的双重功能HK2抑制剂.
- 化合物106通过准HK2介导的糖解和诱导亡,表现出显著的抗癌潜力.
- 化合物106代表了一种有前途的化合物,用于开发新的抗癌疗法.
更多相关视频
09:39Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
Published on: September 17, 2019
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Dipeptidyl Peptidase 4 Inhibitors
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Depolarizing Blockers: Mechanism of Action
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
